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PPulmonary Hypertension
ncreased [18F]Fluorodeoxyglucose Accumulation
n Right Ventricular Free Wall in Patients With
ulmonary Hypertension and the Effect of Epoprostenol
inako Oikawa, MD,* Yutaka Kagaya, MD, PHD,* Hiroki Otani, MD, PHD,*
asahito Sakuma, MD, PHD,* Jun Demachi, MD,* Jun Suzuki, MD, PHD,* Tohru Takahashi, MD, PHD,*
un Nawata, MD, PHD,* Tatsuo Ido, PHD,† Jun Watanabe, MD, PHD,* Kunio Shirato, MD, PHD*
endai, Japan
OBJECTIVES We examined whether right ventricular (RV) [18F]fluorodeoxyglucose (FDG) accumulation is
increased in patients with pulmonary hypertension using gated positron emission tomography
(PET) and whether RV FDG accumulation changes after therapy with epoprostenol.
BACKGROUND Myocardial glucose utilization is increased in animal models with ventricular pressure overload.
METHODS We performed gated FDG-PET in 24 patients with pulmonary hypertension. The RV
standardized uptake value (SUV) of FDG was corrected for the partial volume effect based on the
wall thickness measured by electron-beam computed tomography or magnetic resonance imaging.
RESULTS The corrected RV SUV of FDG was significantly correlated with the pulmonary vascular
resistance, mean pulmonary artery pressure, right atrial pressure, RV wall stress, and plasma brain
natriuretic peptide levels, but not with the RV wall thickness and mass. After pulmonary
vasodilator therapy with epoprostenol for three months, the corrected RV SUV of FDG
significantly decreased in the responders, but not in the non-responders, and the percentage
change of the corrected RV SUV of FDG was significantly correlated with the percentage change
of the pulmonary vascular resistance (r  0.78; p  0.01) and RV systolic wall stress (r  0.76;
p  0.05).
CONCLUSIONS The RV FDG accumulation corrected for the partial volume effect was significantly increased in
accordance with the severity of the RV pressure overload (i.e., the RV peak-systolic wall stress) in
patients with pulmonary hypertension. Furthermore, the corrected RV FDG accumulation was
decreased after the treatment with epoprostenol in accordance with the degree of reduction in the
pulmonary vascular resistance and RV peak-systolic wall stress. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.0651849–55) © 2005 by the American College of Cardiology Foundation
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phronic ventricular pressure or volume overload has been
hown to alter the myocardial preference for energy substrates
1–5). Our previous study and others (1–3) demonstrated that
yocardial glucose uptake was increased, whereas free fatty
cid analogue uptake was decreased, in animal models of
hronic left ventricular (LV) pressure overload. In humans,
yocardial fatty acid metabolism has been shown to be altered
n hypertrophied LV myocardium induced by chronic hyper-
ension (6). In right ventricular (RV) pressure overload due to
ulmonary artery constriction in rats, we demonstrated not
nly that myocardial glucose utilization in the RV free wall
ncreased, but the regional profiles of substrate utilization in
he interventricular septum and the LV free wall were also
ltered (5). Our previous clinical study with positron emission
omography (PET) demonstrated that myocardial [18F]fluoro-
eoxyglucose (FDG) accumulation was increased in the inter-
entricular septum compared with the LV free wall in patients
ith chronic RV volume overload due to atrial septal defect,
nd that the FDG accumulation in the RV free wall was also
From the *Department of Cardiovascular Medicine, Tohoku University Graduate
chool of Medicine, Sendai, Japan; and the †Cyclotron and Radioisotope Center,
ohoku University, Sendai, Japan.n
Manuscript received November 29, 2004; revised manuscript received January 16,
005, accepted February 22, 2005.ncreased in those patients compared with the control subjects,
lthough we did not correct the radioactivity for the RV free
all thickness (7). However, it is unclear whether FDG
ccumulation in the RV free wall, corrected for the partial
olume effect, which is derived from the relatively thin RV free
all thickness, increases in patients with chronic RV pressure
verload. Furthermore, it is also unclear whether myocardial
DG accumulation in the RV free wall changes after treatment
ith epoprostenol, which has been shown to greatly improve
he quality of life and prognosis of patients with primary
ulmonary hypertension (8,9).
In the present study, we examined whether FDG accu-
ulation in the RV free wall increases in patients with
rimary pulmonary hypertension and chronic thromboem-
olic pulmonary hypertension using gated PET with FDG.
e also examined whether RV FDG accumulation changes
fter therapy with epoprostenol in patients with primary
ulmonary hypertension.
ETHODS
tudy population. From among a total of 38 consecutive
atients who were diagnosed as having precapillary pulmo-
ary hypertension in our institute from March 2001 to June
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ue to diabetes mellitus or glucose intolerance, and seven
atients were excluded due to unstable hemodynamic con-
itions. The remaining 24 patients were enrolled in the
resent study. Using right heart catheterization, a diagnosis
f precapillary pulmonary hypertension was made if the
ean pulmonary artery pressure was higher than 25 mm Hg
t rest and the pulmonary capillary wedge pressure was 12
m Hg (10,11). The classification into primary or second-
ry precapillary pulmonary hypertension was performed
ccording to World Health Organization standards (12).
ifteen patients were diagnosed as having primary pulmo-
ary hypertension and nine patients as having chronic
hromboembolic pulmonary hypertension. Coronary an-
iography was also performed in all the patients to exclude
oronary artery disease. Medications included calcium chan-
el blockers (n  15), angiotensin-converting enzyme
nhibitors or angiotensin II receptor blockers (n  14),
igoxin (n  5), diuretics (n  9), and nasal oxygen
upplementation (n 12) in various combinations. All nine
atients with chronic thromboembolic pulmonary hyperten-
ion received anticoagulants. Right heart catheterization
nd the measurement of the plasma brain natriuretic peptide
BNP) level were performed within two weeks from the PET
tudy. Continuous intravenous epoprostenol (Flolan,
laxo-SmithKline, Middlesex, United Kingdom) was ini-
iated in 10 patients with primary pulmonary hypertension
ecause these patients were markedly symptomatic (New
ork Heart Association functional class III or class IV)
espite optimal medical therapy. Epoprostenol was started
t a dose of 0.5 ng/kg/min and gradually increased weekly
y 1 ng/kg/min. We performed the second PET, magnetic
esonance imaging (MRI) or electron-beam computed to-
ography (EBCT), and right heart catheterization after the
reatment with epoprostenol for three months in the 10
atients treated with epoprostenol. The purpose and nature
f the present study were approved by the Committee for
he Administration of Radioactive Substances of Tohoku
niversity School of Medicine. Written informed consent
as obtained from all subjects before each study.
ET. Positron emission tomography was performed with
n SET-2400W PET scanner (Shimadzu, Kyoto, Japan).
Abbreviations and Acronyms
BNP  brain natriuretic peptide
EBCT  electron-beam computed tomography
ECG  electrocardiogram/electrocardiography
FDG  [18F]fluorodeoxyglucose
LV  left ventricle/ventricular
MRI  magnetic resonance imaging
PET  positron emission tomography
ROI  region of interest
RV  right ventricle/ventricular
SUV  standardized uptake valuehe scanner had an axial and transverse field of view of E0 cm and 59 cm, respectively, yielding 63 contiguous
ransaxial slices to cover the whole cardiac region. Each
atient fasted at least 8 h before the PET study. We injected
DG (185 MBq) intravenously as a bolus 30 min after 50 g
f oral glucose. The emission scan was started 35 min after
he FDG injection with an electrocardiogram (ECG)-gated
wo-dimensional acquisition. We obtained six to eight
rames per cardiac cycle with a frame separation of 100 ms.
e performed 10-min transmission scan for attenuation
orrection after the emission scan. Plasma concentrations of
lucose, insulin, and free fatty acid were measured just
efore the injection of FDG and after the transmission scan.
he images were reconstructed with a conventional filtered-
ack projection method using a Butterworth-ramp filter
ith a cutoff frequency of 1.25 cm1. The matrix size was
.0 2.0 mm with 128 128 pixels, and the slice thickness
as 3.125 mm.
ata analysis and phantom study. We placed 5 to 14
ircular regions of interest (ROI, 78 mm2/ROI) on the RV
ree wall, the interventricular septum, and the LV free wall
f the end-diastolic transaxial image, and the standardized
ptake value (SUV), which represents myocardial FDG
ptake per unit volume, was calculated as:
SUV mean ROI count (cps⁄pixel) body weight (kg) ⁄
injected dose (mCi) calibration factor (cps⁄mCi)
here cps is counts per second. To correct for the partial
olume effect, a phantom experiment was performed with
oard phantoms of various thickness and the recovery
oefficient curve was obtained. The corrected SUV was
alculated by the following equation:
Corrected SUV SUV⁄recovery coefficient
e also determined RV end-diastolic volume, RV end-
ystolic volume, and RV ejection fraction using RV short-
xial slices of gated FDG-PET and Perfusion and Function
nalysis for Gated SPECT software (pFAST, Sapporo
edical University, Sapporo, Japan) (13).
BCT, MRI, and RV wall stress. All patients underwent
BCT or MRI to determine RV free wall thickness, RV
olume, and mass within two weeks from the PET study.
he decision to employ EBCT or MRI for the measure-
ent was predominantly based on their availability. Eleven
atients underwent EBCT (C-150XP, GE Imatron, San
rancisco, California). The images were acquired in cine
ode with contrast medium by triggering on the peak of the
-wave of the ECG. Two contiguous 7-mm-thick tomo-
raphic images were produced per target ring, with a 3-mm
ap between images from the adjacent target ring. At each
f the 12 levels, 6 to 10 images per cardiac cycle were
roduced in order to cover the total cardiac cycle (each
mage was acquired in 50 ms). End-diastole was defined as
he scan acquired just before the peak of the R wave on the
CG. We visually selected the transaxial slices correspond-
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June 7, 2005:1849–55 FDG-PET in Patients With Pulmonary Hypertensionng to the PET slices based on the tomographic shape of the
V and LV and measured the wall thickness of the RV free
all, the interventricular septum, and the LV free wall at
nd-diastole.
Thirteen patients underwent MRI. The entire left ven-
ricle was covered by transaxial tomograms with a 10-mm
lice thickness. The ECG signal was transmitted by telem-
try to a remote receiver to trigger the acquisition of the
mages by the R-wave of the ECG. The flow-compensated
radient-echo sequence employed a flip angle of 30° and
radient-refocused echoes with an echo time of 12 ms and
repetition time of 28 ms. Therefore, the temporal resolu-
ion for the individual slices was 56 ms. We visually selected
he transaxial slices corresponding to the PET slices on the
asis of the tomographic shape of the RV and LV and
easured the wall thickness of the RV free wall, the
nterventricular septum, and the LV free wall at end-
iastole.
We also estimated the RV meridianal peak systolic wall
tress according to the following equation (14):
RV meridianal peak systolic wall stress
1.35DP⁄4T (1 T⁄D)
here D is end-systolic RV cavity diameter, P is peak-
ystolic RV pressure, and T is end-systolic RV free wall
hickness, measured from right heart catheterization and
able 1. Clinical Characteristics of the Patients With
ulmonary Hypertension (n  24)
Normal
Range
ge (yrs) 45  19 (16–76)
ender (M/F) 7/17
ody mass index 21.7  3.2 (14.8–26.3)
tiology of pulmonary
hypertension
Primary/chronic
thromboembolic
15/9
YHA functional class
(II/III/IV)
8/12/4
rain natriuretic peptide
(pg/ml)
216  228 (8–743)
ean pulmonary artery
pressure (mm Hg)
52  14 (30–81) 9–19*
V systolic pressure
(mm Hg)
85  22 (42–126) 15–30*
ight atrial pressure
(mm Hg)
6  4 (2–14) 1–5*
ulmonary vascular resistance
(Wood units)
14  6 (4–31) 0.3–1.6*
ardiac index (l/min/m2) 2.2  0.5 (1.2–3.5) 2.5–3.5†
V end-diastolic volume
index (ml/m2)
103  41 (55–233) 75  13‡
V ejection fraction (%) 35  13 (11–58) 61  7†
V mass index (g/m2) 68  25 (27–117) 26  5†
alues are mean  SD. The ranges are shown in the parentheses. The normal values
re from references 15 (*), 16 (†), and 17 (‡).
NYHA  New York Heart Association; RV  right ventricular.RI or EBCT.
c
mtatistical analysis. All values are expressed as mean 
D. Statistical analysis of differences between groups was
one by unpaired Student t test or paired Student t test
here appropriate. Correlations between the two parame-
ers were determined by simple linear regression analysis.
tatistical significance was accepted at a level of p  0.05.
ESULTS
able 1 shows the baseline clinical characteristics, right
eart catheterization data, and EBCT or MRI data. The
ean pulmonary artery pressure, RV systolic pressure,
ulmonary vascular resistance, and plasma BNP were highly
ncreased compared with the normal values (15,16), al-
hough the scatter of the plasma BNP was rather large.
ight ventricular end-diastolic volume and RV mass index
ere increased and RV ejection fraction was decreased,
ecause the reported normal RV end-diastolic volume, RV
jection fraction, and RV mass are 75 13 ml/m2, 61 7 %
nd 26  5 g/m2 (17). Figure 1 shows the representative
idventricular transaxial PET images of patients with mild
Fig. 1A) and severe (Fig. 1B) primary pulmonary hyper-
ension. The SUV of FDG corrected for the partial volume
ffect in the RV free wall was significantly correlated with
he mean pulmonary artery pressure (r  0.78; p  0.001;
ig. 2A), right atrial pressure (r  0.50; p  0.05; Fig. 2B),
ulmonary vascular resistance (r 0.67; p 0.01; Fig. 2C),
all stress in the RV free wall (r  0.74; p  0.001; Fig.
D), and plasma BNP level (r  0.54; p  0.01; Fig. 2E).
mong these five independent variables, the mean pulmo-
ary artery pressure and wall stress in the RV free wall were
orrelated tightly with the RV SUV of FDG, and those two
ndependent variables were also significantly correlated with
ach other (r  0.58, p  0.01). The SUV of FDG
orrected for the partial volume effect in the RV free wall
id not correlate with the cardiac index, RV end-diastolic
olume index, RV ejection fraction, or RV mass index.
lthough the RV SUV of FDG that was not corrected for
he partial volume effect was significantly correlated with the
igure 1. The midventricular transaxial [18F]fluorodeoxyglucose (FDG)
ositron emission tomography (PET) images of the patients with mild (A,
ean pulmonary artery pressure, 33 mm Hg) and severe pulmonary
ypertension (B, mean pulmonary artery pressure, 81 mm Hg). In each
mage, the right ventricular (RV) free wall is at upper left, the interven-
ricular septum at middle, and the left ventricular (LV) free wall at lower
ight. In the patients with severe pulmonary hypertension, the RV FDG
ccumulation increased compared with that in the patients with mild
ulmonary hypertension. The RV standardized uptake value of FDG
orrected for the partial volume effect was 6.6 and 12.7 in the patients with
ild and severe pulmonary hypertension, respectively.
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FDG-PET in Patients With Pulmonary Hypertension June 7, 2005:1849–55all thickness of the RV free wall (r  0.58; p  0.01; Fig.
A), the correlation was not significant after the RV SUV of
DG was corrected for the partial volume effect (Fig. 3B).
he RV end-diastolic volume index (r  0.94; p  0.001;
ig. 4A) and RV end-systolic volume index (r  0.93; p 
.001; Fig. 4B) determined by pFAST were closely corre-
ated with those determined by EBCT or MRI, although
FAST analysis was impossible in three patients because
heir FDG accumulation in the RV free wall was too low.
he correlation between the RV ejection fraction and that
etermined by pFAST and that by EBCT or MRI was
eaker (r  0.48; p  0.05; Fig. 4C).
nsulin, glucose, and free fatty acid concentrations. Table 2
hows the plasma concentrations of insulin, glucose, and
ree fatty acids during the initial PET study performed in
he 24 patients. The plasma concentrations of insulin,
lucose, and free fatty acids both 30 min and 80 min after
0 g oral glucose did not correlate with the SUV of FDG
orrected for the partial volume effect in the RV free wall
data not shown).
hange of RV SUV of FDG corrected for the partial
olume effect after the pulmonary vasodilator therapy. In
0 patients with primary pulmonary hypertension treated
ith epoprostenol for three months, FDG-PET, EBCT or
RI, and right heart catheterization were performed before
nd after the three-month treatment. The average dose of
poprostenol was 15  2 ng/kg/min. We divided those
atients into responders and nonresponders according to
hether or not the pulmonary vascular resistance was
educed by 30% after the treatment with epoprostenol for
hree months. This was because a reduction of the pulmo-
igure 2. Correlations between the right ventricular (RV) standardized u
olume effect and mean pulmonary artery pressure (A), right atrial pressure
lasma brain natriuretic peptide (BNP) level (E).ary vascular resistance by 30% after epoprostenol treat-
o
Fent for three months has been reported to be an indepen-
ent predictor of poor survival by Sitbon et al. (18).
ccording to the results of the second right heart catheter-
zation after the three-month epoprostenol treatment, five
atients were classified into the responder group and the
ther five patients into the nonresponder group.
Figures 5A and 5B show the midventricular transaxial
ET images of a responder before and after the treatment
ith epoprostenol for three months. In the responder group,
hose pulmonary vascular resistance was significantly re-
uced by 10.1  1.9 Wood units, the RV SUVs of FDG
orrected for the partial volume effect, BNP, mean pulmo-
ary artery pressure, cardiac index, RV ejection fraction, and
V meridianal peak systolic wall stress were significantly
mproved after the treatment with epoprostenol for three
onths. However, the RV volume, RV mass index, and RV
igure 3. Correlations between the RV wall thickness and the RV SUV of
DG when not corrected for the partial volume effect (A) and the RV SUV
value (SUV) of [18F]fluorodeoxyglucose (FDG) corrected for the partial
pulmonary vascular resistance (C), wall stress in the RV free wall (D), andptakef FDG corrected for the partial volume effect (B). Abbreviations as in
igures 1 and 2.
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June 7, 2005:1849–55 FDG-PET in Patients With Pulmonary Hypertensionall thickness did not change (Table 3). In the 10 patients
reated with epoprostenol, the percentage change of the
orrected RV SUV of FDG was significantly correlated with
he percentage change of the pulmonary vascular resistance
Fig. 6A) and wall stress in the RV free wall (Fig. 6B). The
lasma concentrations of insulin, glucose, and free fatty
cids both 30 min (insulin: 54  33 IU/ml vs. 55  44
IU/ml; glucose: 132  24 mg/dl vs. 131  23 mg/dl; free
atty acids: 0.47  0.34 mEq/l vs. 0.45  0.16 mEq/l) and
0 min (insulin: 23  14 IU/ml vs. 34  16 IU/ml;
lucose: 109  23 mg/dl vs. 128  31 mg/dl; free fatty
cids: 0.21  0.31 mEq/l vs. 0.16  0.14 mEq/l) after 50 g
ral glucose were not significantly different between the first
nd the second PET studies, respectively.
ISCUSSION
orrelation between the FDG accumulation in RV free
all and RV pressure overload. First, the increased wall
hickness in the patients with pulmonary hypertension
ight affect the recovered count through the partial volume
ffect. In the present study, however, we corrected for the
artial volume effect based on the RV free wall thickness
easured by EBCT or MRI and the recovery coefficient
erived from the phantom study and found that the RV
UV of FDG corrected for the partial volume effect was
orrelated with the severity of the RV pressure overload. It
s unlikely, therefore, that the increased RV FDG accumu-
ation can be explained by the increased RV free wall
hickness.
Second, myocardial ischemia has been shown to acceler-
te myocardial glucose uptake (19). A recent scintigraphic
able 2. Plasma Concentration of Insulin, Glucose, and Free
atty Acids During PET Study
Time After 50 g Oral Glucose 30 min 80 min
nsulin (IU/ml) 41  28 29  16
lucose (mg/dl) 139  23 139  46
ree fatty acids (mEq/l) 0.55  0.32 0.14  0.22
igure 4. The RV end-diastolic volume index (RVEDVI) (A) and RV en
nalysis for gated SPECT software (pFAST) were closely correlated with t
esonance imaging (MRI), although pFAST analysis was impossible in th
he correlation between the RV ejection fraction (RVEF) (C) determined
igures 1 and 2.t
A
alues are mean  SD.
PET  positron emission tomography.tudy by Gomez et al. (20) demonstrated perfusion abnor-
alities in the RV free wall in patients with severe primary
ulmonary hypertension. Although all patients in the
resent study showed normal coronary arteriographies, we
annot exclude the possibility that myocardial ischemia due
o severe RV hypertrophy might have increased the RV
DG accumulation (21).
Third, the myocardial preference for energy substrates is
hifted from free fatty acids toward glucose in the develop-
ent of cardiac hypertrophy. Our previous animal study
howed that glucose utilization in rats was increased,
hereas free fatty acid utilization was decreased or un-
hanged in the hypertrophied myocardium because of long-
erm LV or RV pressure overload (1,5). Although we did
ot investigate free fatty acid metabolism in the present
tudy, the shift of the preference for energy substrates from
ree fatty acids to glucose in hypertrophied myocardium
ight be responsible for the increased RV FDG accumu-
ation.
Finally, the increased RV workload would also explain
he increased FDG accumulation in the RV free wall. Gertz
t al. (22) reported that myocardial glucose utilization
ncreases with exercise in humans. Camici et al. (23)
eported that both myocardial oxygen consumption and
lucose uptake increased linearly during incremental atrial
igure 5. Representative midventricular transaxial FDG PET images of a
atient with primary pulmonary hypertension before and after the pulmo-
ary vasodilator therapy with epoprostenol for three months. Before the
ulmonary vasodilator therapy, the RV FDG accumulation was highly
ncreased and the corrected RV SUV of FDG was 13.4 (A). After the
tolic volume index (RVESVI) (B) determined by perfusion and function
etermined by electron-beam computed tomography (EBCT) or magnetic
tients because their FDG accumulation in the RV free wall was too low.
FAST and that by EBCT or MRI was weaker. Other abbreviations as ind-sys
hose d
ree pa
by pherapy, the corrected RV SUV of FDG markedly decreased to 7.5 (B).
bbreviations as in Figures 1 and 2.
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FDG-PET in Patients With Pulmonary Hypertension June 7, 2005:1849–55acing in humans. In the present study, the RV wall stress
as significantly increased in the patients with pulmonary
ypertension owing to the increased RV diameter and RV
ystolic pressure. The increased RV wall stress may have
ncreased myocardial oxygen consumption and energy sub-
trate demand, and may explain the increased RV FDG
ccumulation in the patients with pulmonary hypertension.
his notion might be supported by the fact that the
orrected RV SUV of FDG was significantly correlated with
he wall stress in the RV free wall, but not with the degree
f RV hypertrophy, and also by the fact that the corrected
V SUV of FDG was significantly decreased in the re-
ponders to the epoprostenol treatment, although the RV
ypertrophy did not regress.
ffects of pulmonary vasodilator therapy on FDG accu-
ulation in RV free wall. In the present study, 5 of 10
atients treated with epoprostenol showed improvements in
ulmonary vascular resistance compared with the baseline
fter the 3-month treatment with epoprostenol. In these five
esponders, the corrected RV FDG accumulation as well as
ean pulmonary vascular resistance, mean pulmonary artery
ressure, and RV meridianal peak systolic wall stress were
ignificantly decreased, although the RV end-diastolic vol-
me, the RV mass index, and the RV wall thickness
easured by EBCT or MRI did not change significantly.
ur findings regarding the RV volume and RV wall motion
re concordant with the echocardiographic study by
inderliter et al. (24) showing that although the RV
nd-diastolic area was unchanged, the RV wall motion
mproved after epoprostenol therapy for three months.
urthermore, as discussed in the previous section, the
ncreased RV FDG accumulation at baseline in the patients
ith primary pulmonary hypertension can possibly be ex-
lained by the increased wall stress due to RV pressure
verload rather than RV hypertrophy itself, because the RV
DG accumulation decreased according to the degree of
able 3. Paired Data Before and After Pulmonary Vasodilator T
Respon
Before
Therapy
ulmonary vascular resistance (Wood units) 20.1  7.0 1
ean pulmonary artery pressure (mm Hg) 64.4  3.9 5
V systolic pressure (mm Hg) 100  6
ight atrial pressure (mm Hg) 6.4  2.4
ardiac index (l/min/m2) 2.1  0.6
VEDVI (ml/m2) 110  23 1
nd systolic RV cavity diameter (mm) 53  4
V ejection fraction (%) 27  9
V mass index (g/m2) 76  30
V wall thickness (mm) 6.0  2.5
V meridianal peak systolic wall stress (g/cm2) 135  18 1
rain natriuretic peptide (pg/ml) 362  238
V SUV of FDG corrected for the partial
volume effect
12.0  1.8
alues are mean  SD.
FDG  [18F]fluorodeoxyglucose; RV  right ventricular; RVEDVI  right veneduction in the RV wall stress without a regression of the
p
wV mass index after the epoprostenol therapy for three
onths. The RV metabolic change, therefore, may not
ecessarily be associated with a structural alteration if the
eart is able to alter substrate accumulation with more
lacrity than it is able to alter structure. Whether RV
yocardial metabolic changes may contribute to the func-
ional changes and whether myocardial metabolic modula-
ion may improve the mortality and morbidity of patients
ith pulmonary hypertension remain to be elucidated.
Intravenous prostacyclin has been shown to increase the
nsulin sensitivity of the skeletal muscles (25). Therefore,
ecreased RV FDG accumulation by epoprostenol might
imply reflect an increase in insulin sensitivity and resultant
ncrease in FDG accumulation peripherally. To examine
his possibility, we calculated FDG accumulation in the
rachial muscles using the same PET images as those used
or the measurement of myocardial FDG accumulation in
ve patients who showed a decrease in RV FDG accumu-
ation after epoprostenol for three months. The SUV of
DG in the biceps brachii muscle after the epoprostenol
herapy was not significantly different from that at the
igure 6. Correlations between the percentage change of RV SUV of FDG
orrected for the partial volume effect and the percentage change of the
y of the Responder and Nonresponder Groups
n  5) Nonresponder (n  5)
r
py p Value
Before
Therapy
After
Therapy p Value
1.9 0.05 15.2  4.3 14.8  5.2 NS
6.6 0.05 63.4  14.5 64.0  12.4 NS
7 NS 103  21 103  24 NS
3.4 NS 8.4  4.2 7.8  1.5 NS
0.4 0.05 2.4  0.7 2.5  0.6 NS
28 NS 111  42 121  52 NS
10 NS 53  17 46  9 NS
9 0.05 34  10 36  7 NS
27 NS 86  29 92  43 NS
2.5 NS 5.4  3.2 5.5  3.0 NS
20 0.05 113  40 107  40 NS
59 0.05 249  267 176  143 NS
2.2 0.01 11.4  2.1 11.8  1.9 NS
r end-diastolic volume index; SUV  standardized uptake value.herap
der (
Afte
Thera
0.1 
5.0 
93 
4.8 
3.1 
05 
48 
41 
74 
5.7 
01 
54 
7.2 ulmonary vascular resistance and peak-systolic wall stress in the RV free
all. Abbreviations as in Figures 1 and 2.
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June 7, 2005:1849–55 FDG-PET in Patients With Pulmonary Hypertensionaseline (0.68  0.25 vs. 0.70  0.15, respectively). There-
ore, the increased FDG accumulation in the peripheral
keletal muscle would be unlikely to explain the decreased
V FDG accumulation in our patients.
tudy limitations. We measured the BNP level and RV
nd right atrial structural and functional data within two
eeks of the PET study, but not on the day of the PET
tudy. This may be a limitation because these parameters
ight have changed during the two weeks. It may be also a
imitation to use EBCT and MRI for the measurement of
V structure because of a possible difference in the mea-
urement between the two different modalities. We did not
easure plasma sympathetic hormones in the present study.
ympathetic hormones would increase myocardial workload
nd oxygen consumption (26). The myocardial substrate
reference would also be affected by sympathetic stress
ormones. Finally, we did not perform myocardial perfusion
maging in the present study. Therefore, we do not know
hether myocardial blood flow in the RV free wall increases
n accordance with the severity of RV pressure overload.
urther study using myocardial perfusion imaging with
orrection for the partial volume effect is required to answer
his question.
onclusions. The RV FDG accumulation corrected for
he partial volume effect was significantly increased in
ccordance with the severity of RV pressure overload (i.e.,
he RV peak-systolic wall stress) in patients with pulmonary
ypertension. Furthermore, the corrected RV FDG accu-
ulation was decreased after the treatment with epoproste-
ol in accordance with the degree of reduction in the
ulmonary vascular resistance and RV peak-systolic wall
tress.
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